Authors

Latest:

Dr. O'Connell on a Phase II Trial to Evaluate Optune in Grade III Brain Cancer

Daniel O'Connell, MD, University of California at Los Angeles, discusses a phase II trial testing the benefits of tumor treating fields with Optune for bevacizumab-naive patients with grade III malignant glioma.

Daniel P. Petrylak, MD

Daniel P. Petrylak, MD, is a professor of medicine (medical oncology) and urology, as well as the chief of Genitourinary Oncology, at Yale School of Medicine and Smilow Cancer Hospital

Latest:

Dr Petrylak on the Importance of Early Detection to Minimize Treatment Intensity in Testicular Cancer

Daniel P. Petrylak, MD, Yale

Daniel P. Petrylak, MD, Yale School of Medicine

Daniel P. Petrylak, MD, Yale University Cancer Center

Daniel Petrylak, MD, Yale School of Medicine

Latest:

The Emerging Role of Chemotherapy in Metastatic Prostate Cancer

Daniel Petrylak, MD, Yale University

Daniel Pollyea, MD, MS, University of Colorado, Anschutz Medical Campus

Daniel R. Couriel, MD

Latest:

Dr. Couriel Discusses Treating GVHD With Photopheresis

Dr. Daniel Couriel, from the Unversity of Michigan Comprehensive Cancer Center, Discusses Treating GVHD With Photopheresis

Daniel R. Saltzstein, MD, Urology San Antonio

Daniel R. Vlock, MD

Latest:

Dr. Vlock on Anti—CD20 Interleukin-2 Immunocytokine in NHL

Daniel R. Vlock, MD, founder and CEO, Alopexx Pharmaceuticals, discusses a phase I/II study of an antiâ€“CD20 interleukin-2 immunocytokine in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).

Daniel Sargent, PhD

Latest:

Daniel Sargent on International Collaboration for Colon Cancer Research

Daniel Sargent, PhD, professor of Oncology and Biostatistics, Mayo Clinic in Rochester, Minnesota, discusses the IDEA initiative, which is an international study to examine if patients with colon cancer would benefit from reducing the duration of adjuvant therapy from 3 months to 6 months to reduce side effects and cost.

Daniel V. Catenacci, MD, University of Chicago

Latest:

Global Updates in Advanced Gastric Cancer from ESMO 2020

Daniel Vaena, MD

Latest:

Dr. Vaena on Major Advances in Metastatic Prostate Cancer

Daniel Vaena, MD, hematologist/medical oncologist and hematologist, West Cancer Center, discusses progress made in the treatment of patients with metastatic prostate cancer.

Daniel Verina, NP, Mount Sinai Health System

Latest:

Impact of Upcoming Daratumumab Subcutaneous Formulation for Treatment of Multiple Myeloma

Daniel Von Hoff, MD

Latest:

Dr. Daniel Von Hoff on Combination Treatments for Late Stage Pancreatic Cancer

Daniel Von Hoff, MD, the Physician-in-Chief and Director of Translational Research at the Translational Genomics Research Institute (TGen) and a special consult with Baylor University College of Medicine, discuses combination treatments for pancreatic cancer.

Daniela Bota, MD, PhD

Latest:

Dr. Bota on Marizomib in Patients with Glioma

Daniela Bota, MD, PhD, medical director, Neuro-Oncology Program, associate professor, Neurology School of Medicine, UC Irvine Health, discusses marizomib for the treatment of patients with glioma.

Daniela Bota, MD, UC Irvine Medical Center

Daniela Molena, MD

Latest:

Dr. Molena on Lung-Sparing Surgery in Early-Stage Lung Cancer

Daniela Molena, MD, director, Esophageal Surgery Program, Memorial Sloan Kettering Cancer Center, discusses the use of lung-sparing surgery in early-stage lung cancer.

Danielle Brander, MD

Latest:

Dr Brander on Findings From the TRANSCEND CLL 004 Trial in Relapsed/Refractory CLL/SLL

Danielle M. Brander, MD, discusses the primary analysis of the phase 1/2 TRANSCEND CLL 004 trial in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.